Every round on record, with the sources behind each and the investors on them.
Zenflow is a medical device company developing innovative therapies for the treatment of benign prostatic hyperplasia (BPH).
zenflow.comLinkedInSouth San Francisco, Calif.MedtechFounded 201444 people
8 sources · checked 1 time, last 1h ago
HSBC Bank USA, N.A. and Trinity Capital are described as venture-debt providers, not equity-round investors, so they are excluded from the syndicate.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series D+ Series D financing | $52M | 2026-10-05 | Cook Medical | 8 outlets. #5 in Trending |
8 sources · checked 1 time, last 1h ago [ VERIFIED ] read against 4 of 8 sources HSBC Bank USA, N.A. and Trinity Capital are described as venture-debt providers, not equity-round investors, so they are excluded from the syndicate. | ||||
Zenflow builds minimally invasive medical devices—led by its reversible Zenflow Spring implant—to treat urinary symptoms caused by an enlarged prostate for men with benign prostatic hyperplasia.
BPH affects more than 30 million U.S. men, while the company says existing drug and surgical choices can bring limited relief, side effects, or procedural trauma; Zenflow’s Spring is positioned as a minimally invasive, reversible office treatment that avoids tissue removal and post-procedure catheterization. The latest $52 million Series D led by Cook Medical, together with an exclusive U.S. distribution agreement, is intended to accelerate commercialization after FDA approval, while the BREEZE study reported a 37% mean symptom-score improvement at 12 months and 99% of men avoiding catheterization.
Checked against 10 sources today
Via Alexandria from FullEnrich: type, industry
Also named as backers in company research: Medical Technology Venture Partners, Golden Seeds, Astia Angels, CloudStone Capital, SV Tech Ventures, National Institutes of Health (NIH), National Science Foundation (NSF), Y Combinator, StartX, Rosenman Institute at QB3